| Prev Close | 86.37 |
| Open | 86.40 |
| Day Low/High | 86.25 / 87.40 |
| 52 Wk Low/High | 55.06 / 89.69 |
| Volume | 2.55M |
| Avg Volume | 5.54M |
| Exchange | NYSE |
| Shares Outstanding | 1.59B |
| Market Cap | 136.01B |
| EPS | 3.60 |
| P/E Ratio | 16.22 |
| Div & Yield | 2.56 (3.00%) |
Don't be distracted and start buying high and selling low, says Jim Cramer. A good example? Don't trade Apple, own it.
- In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse
The most recent short interest data has been released for the 08/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Hedge fund managers are out with their top stock picks. So who made the list?
Evercore ISI analyst Josh Schimmer is bullish on biotech.
Jim Cramer is bullish on EPR Properties, Activision Blizzard, AbbVie, and ON Semiconductor.
Cramer says this is not the end of the selloff. That's why you should be mentally and financially ready for panic moves -- and opportunities.
- MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment
- MAVIRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*
What differentiated traders who were injured yesterday from those able to whether a sudden storm? Diversification.
Stock futures are lower.
U.S. stock futures fall as earnings from Amazon.com disappoint.
Wall Street's first glimpse at the second quarter.
- If approved, HUMIRA® will be the first biologic treatment option in the European Union for pediatric patients with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy
Remarkable data was released from Vertex's triple regiment combination trials.
Tech companies aren't the only ones seeing their shares rise this year.
Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.
Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...
The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.
